Published in J Clin Oncol on March 28, 2011
Adjuvant radiotherapy for stage I endometrial cancer. Cochrane Database Syst Rev (2012) 1.16
Beyond treatment - Psychosocial and behavioural issues in cancer survivorship research and practice. EJC Suppl (2014) 0.96
Lower limb lymphedema in gynecological cancer survivors--effect on daily life functioning. Support Care Cancer (2013) 0.93
Adjuvant vaginal cuff brachytherapy for high-risk, early stage endometrial cancer. J Contemp Brachytherapy (2014) 0.87
Assessment of endometrial sampling as a predictor of final surgical pathology in endometrial cancer. Br J Cancer (2013) 0.82
Adjuvant vaginal brachytherapy as a part of management in early endometrial cancer. J Contemp Brachytherapy (2012) 0.82
Assessment of patient-reported measures of bowel function before and after pelvic radiotherapy: an ancillary study of the North Central Cancer Treatment Group study N00CA. Support Care Cancer (2012) 0.82
Bladder (ICRU) dose point does not predict urinary acute toxicity in adjuvant isolated vaginal vault high-dose-rate brachytherapy for intermediate-risk endometrial cancer. J Contemp Brachytherapy (2015) 0.81
Outcome of Endometrial Cancer Stage IIIA with Adnexa or Serosal Involvement Only. Obstet Gynecol Int (2011) 0.81
Endometrial cancer. Obstet Gynecol Clin North Am (2012) 0.79
Safety of adjuvant intensity-modulated postoperative radiation therapy in endometrial cancer: Clinical data and dosimetric parameters according to the International Commission on Radiation Units (ICRU) 83 report. Rep Pract Oncol Radiother (2015) 0.78
Urinary adverse effects of pelvic radiotherapy. Transl Androl Urol (2014) 0.77
Feasibility study of pelvic helical IMRT for elderly patients with endometrial cancer. PLoS One (2014) 0.76
Pelvic radiotherapy and sexual function in women. Transl Androl Urol (2015) 0.76
Rectal bleeding after radiation therapy for endometrial cancer. Radiother Oncol (2015) 0.75
Radiotherapy for Colorectal Cancer: Current Standards and Future Perspectives. Visc Med (2016) 0.75
A novel method for vaginal cylinder treatment planning: a seamless transition to 3D brachytherapy. J Contemp Brachytherapy (2012) 0.75
Emotional and sexual concerns in women undergoing pelvic surgery and associated treatment for gynecologic cancer. Transl Androl Urol (2015) 0.75
Endometrial cancer - reduce to the minimum. A new paradigm for adjuvant treatments? Radiat Oncol (2011) 0.75
Intensity-Modulated Radiation Therapy Versus 3D Conformal Radiotherapy for Postoperative Gynecologic Cancer: Are They Covering the Same Planning Target Volume? Cureus (2016) 0.75
Patients' and clinicians' preferences for adjuvant chemotherapy in endometrial cancer: an ANZGOG substudy of the PORTEC-3 intergroup randomised trial. Br J Cancer (2016) 0.75
Outcome and Predictive Factors in Uterine Carcinosarcoma Using Postoperative Radiotherapy: A Rare Cancer Network Study. Rare Tumors (2016) 0.75
Radiotherapy: avoiding EBRT for those without high-risk endometrial cancer. Nat Rev Clin Oncol (2011) 0.75
Is there a subset of patients with recurrent cancer in the vagina who are not candidates for interstitial brachytherapy that can be treated with multichannel vaginal brachytherapy using graphic optimization? J Contemp Brachytherapy (2015) 0.75
American Brachytherapy Task Group Report: Adjuvant vaginal brachytherapy for early-stage endometrial cancer: A comprehensive review. Brachytherapy (2016) 0.75
Baseline risk of recurrence in stage I-II endometrial carcinoma. J Gynecol Oncol (2018) 0.75
Impact of a higher radiation dose on local control and survival in breast-conserving therapy of early breast cancer: 10-year results of the randomized boost versus no boost EORTC 22881-10882 trial. J Clin Oncol (2007) 7.51
Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol (2006) 5.20
Survival after relapse in patients with endometrial cancer: results from a randomized trial. Gynecol Oncol (2003) 2.81
Involved-field radiotherapy for advanced Hodgkin's lymphoma. N Engl J Med (2003) 2.35
Update of Dutch multicenter dose-escalation trial of radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys (2008) 2.33
Acute and late complications after radiotherapy for prostate cancer: results of a multicenter randomized trial comparing 68 Gy to 78 Gy. Int J Radiat Oncol Biol Phys (2005) 2.31
Relationship between age and axillary lymph node involvement in women with breast cancer. J Clin Oncol (2009) 2.27
Impact of pathological characteristics on local relapse after breast-conserving therapy: a subgroup analysis of the EORTC boost versus no boost trial. J Clin Oncol (2009) 2.26
Quality of life among long-term breast cancer survivors: a systematic review. Eur J Cancer (2005) 2.25
Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. J Natl Cancer Inst (2002) 2.25
High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study. J Clin Oncol (2013) 2.22
High EVI1 expression predicts poor survival in acute myeloid leukemia: a study of 319 de novo AML patients. Blood (2002) 2.01
Impact of cancer on adherence to glucose-lowering drug treatment in individuals with diabetes. Diabetologia (2015) 1.96
Biallelic mutations in the CEBPA gene and low CEBPA expression levels as prognostic markers in intermediate-risk AML. Hematol J (2003) 1.85
Localized volume effects for late rectal and anal toxicity after radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys (2006) 1.71
Unfavourable pattern of metastases in M0 breast cancer patients during 1978-2008: a population-based analysis of the Munich Cancer Registry. Breast Cancer Res Treat (2011) 1.70
Clinical effectiveness of leucoreduced, pooled donor platelet concentrates, stored in plasma or additive solution with and without pathogen reduction. Br J Haematol (2010) 1.66
Predictors of the risk of fibrosis at 10 years after breast conserving therapy for early breast cancer: a study based on the EORTC Trial 22881-10882 'boost versus no boost'. Eur J Cancer (2008) 1.61
Absence of lymphangiogenesis in ductal breast cancer at the primary tumor site. Cancer Lett (2007) 1.61
Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed/progressive aggressive CD20+ NHL: a prospective randomized HOVON trial. Blood (2007) 1.60
Postoperative radiotherapy for Stage 1 endometrial carcinoma: long-term outcome of the randomized PORTEC trial with central pathology review. Int J Radiat Oncol Biol Phys (2005) 1.57
Criteria for defining a complete remission in acute myeloid leukaemia revisited. An analysis of patients treated in HOVON-SAKK co-operative group studies. Br J Haematol (2005) 1.54
Sentinel node micrometastases in breast cancer do not affect prognosis: a population-based study. Breast Cancer Res Treat (2010) 1.52
Point: Vaginal brachytherapy should be a standard adjuvant treatment for intermediate-risk endometrial cancer. Brachytherapy (2011) 1.48
Quality of life after pelvic radiotherapy or vaginal brachytherapy for endometrial cancer: first results of the randomized PORTEC-2 trial. J Clin Oncol (2009) 1.44
International brachytherapy practice patterns: a survey of the Gynecologic Cancer Intergroup (GCIG). Int J Radiat Oncol Biol Phys (2010) 1.44
Association between metformin use and mortality in patients with prostate cancer: explained by confounding by indication? J Clin Oncol (2014) 1.37
Antihypertensive medications and differences in muscle mass in older persons: the Health, Aging and Body Composition Study. J Am Geriatr Soc (2004) 1.36
Comparative analysis of the value of allogeneic hematopoietic stem-cell transplantation in acute myeloid leukemia with monosomal karyotype versus other cytogenetic risk categories. J Clin Oncol (2012) 1.30
Well-being, posttraumatic growth and benefit finding in long-term breast cancer survivors. Psychol Health (2009) 1.24
New opportunities for drug outcomes research in cancer patients: the linkage of the Eindhoven Cancer Registry and the PHARMO Record Linkage System. Eur J Cancer (2009) 1.23
Chemotherapy-induced neuropathy and its association with quality of life among 2- to 11-year colorectal cancer survivors: results from the population-based PROFILES registry. J Clin Oncol (2013) 1.23
Neoadjuvant radiotherapy of primary irresectable unicentric Castleman's disease: a case report and review of the literature. Radiat Oncol (2010) 1.23
Risk stratification of intermediate-risk acute myeloid leukemia: integrative analysis of a multitude of gene mutation and gene expression markers. Blood (2011) 1.21
Fifteen-year radiotherapy outcomes of the randomized PORTEC-1 trial for endometrial carcinoma. Int J Radiat Oncol Biol Phys (2011) 1.18
Long-term cancer survivors experience work changes after diagnosis: results of a population-based study. Psychooncology (2009) 1.17
Outcome of high-risk stage IC, grade 3, compared with stage I endometrial carcinoma patients: the Postoperative Radiation Therapy in Endometrial Carcinoma Trial. J Clin Oncol (2004) 1.16
Bowel, urinary, and sexual problems among long-term prostate cancer survivors: a population-based study. Int J Radiat Oncol Biol Phys (2008) 1.16
Quality of life among long-term non-Hodgkin lymphoma survivors: a population-based study. Cancer (2007) 1.16
Loss of ARID1A expression and its relationship with PI3K-Akt pathway alterations, TP53 and microsatellite instability in endometrial cancer. Mod Pathol (2013) 1.16
Five-year quality of life of endometrial cancer patients treated in the randomised Post Operative Radiation Therapy in Endometrial Cancer (PORTEC-2) trial and comparison with norm data. Eur J Cancer (2011) 1.14
Clinical management of women with metastatic breast cancer: a descriptive study according to age group. BMC Cancer (2006) 1.14
Half of breast cancer patients discontinue tamoxifen and any endocrine treatment before the end of the recommended treatment period of 5 years: a population-based analysis. Breast Cancer Res Treat (2010) 1.13
Barriers to participating in genetic counseling and BRCA testing during primary treatment for breast cancer. Genet Med (2007) 1.12
High-dose Ara-C and beam with autograft rescue in R-CHOP responsive mantle cell lymphoma patients. Br J Haematol (2008) 1.10
Normative data for the EORTC QLQ-C30 and EORTC-sexuality items in the general Dutch population. Eur J Cancer (2010) 1.06
The impact of treatment, socio-demographic and clinical characteristics on health-related quality of life among Hodgkin's and non-Hodgkin's lymphoma survivors: a systematic review. Ann Hematol (2011) 1.05
Scalp cooling for hair preservation and associated characteristics in 1411 chemotherapy patients - results of the Dutch Scalp Cooling Registry. Acta Oncol (2012) 1.03
Synopsis of partial-body radiation diagnostic biomarkers and medical management of radiation injury workshop. Radiat Res (2010) 1.01
Gynecologic Cancer InterGroup (GCIG) consensus review for uterine and ovarian carcinosarcoma. Int J Gynecol Cancer (2014) 1.01
Sexual function after three-dimensional conformal radiotherapy for prostate cancer: results from a dose-escalation trial. Int J Radiat Oncol Biol Phys (2007) 0.99
A high level of fatigue among long-term survivors of non-Hodgkin's lymphoma: results from the longitudinal population-based PROFILES registry in the south of the Netherlands. Haematologica (2012) 0.99
Substantial increase in the use of adjuvant systemic treatment for early stage breast cancer reflects changes in guidelines in the period 1990-2006 in the southeastern Netherlands. Eur J Cancer (2008) 0.99
Trends in the prognosis of patients with primary metastatic breast cancer diagnosed between 1975 and 2002. Breast (2007) 0.99
The relationship of body mass index with quality of life among endometrial cancer survivors: a study from the population-based PROFILES registry. Gynecol Oncol (2013) 0.99
The influence of age and comorbidity on receiving radiotherapy as part of primary treatment for cancer in South Netherlands, 1995 to 2002. Cancer (2006) 0.98
Improved risk assessment of endometrial cancer by combined analysis of MSI, PI3K-AKT, Wnt/β-catenin and P53 pathway activation. Gynecol Oncol (2012) 0.98
Efficacy of a hypofractionated schedule in electron beam radiotherapy for epithelial skin cancer: Analysis of 434 cases. Radiother Oncol (2010) 0.97
GOG-99: ending the controversy regarding pelvic radiotherapy for endometrial carcinoma? Gynecol Oncol (2004) 0.97
BRCA1/2 mutation testing in breast cancer patients: a prospective study of the long-term psychological impact of approach during adjuvant radiotherapy. Breast Cancer Res Treat (2007) 0.97
Dose-volume parameters of the corpora cavernosa do not correlate with erectile dysfunction after external beam radiotherapy for prostate cancer: results from a dose-escalation trial. Int J Radiat Oncol Biol Phys (2007) 0.97
Prognostic significance and interobserver variability of histologic grading systems for endometrial carcinoma. Cancer (2004) 0.97
Health-related quality of life and disease-specific complaints among multiple myeloma patients up to 10 yr after diagnosis: results from a population-based study using the PROFILES registry. Eur J Haematol (2012) 0.95
The course of anxiety and depression for patients with Hodgkin's lymphoma or diffuse large B cell lymphoma: a longitudinal study of the PROFILES registry. J Cancer Surviv (2014) 0.94
Psychometric validation of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Endometrial Cancer Module (EORTC QLQ-EN24). Eur J Cancer (2010) 0.94
Illness perceptions in cancer survivors: what is the role of information provision? Psychooncology (2012) 0.94
Health-related quality of life among thyroid cancer survivors: a systematic review. Clin Endocrinol (Oxf) (2011) 0.93